Hamilton T, DeMatteo R, McClane S, Burke C, Rombeau J, Raper S
Harrison Department of Surgical Research, University of Pennsylvania School of Medicine, Philadelphia, USA.
J Pediatr Surg. 1997 Feb;32(2):373-7. doi: 10.1016/s0022-3468(97)90214-1.
The authors sought to assess the feasibility of in vivo gene transfer to the small intestine using recombinant adenovirus in neonatal and adult mice.
H5.010CMVlacZ is a replication-defective, E1-deleted human type 5 adenovirus, which contains the lacZ gene under the control of a cytomegalovirus promoter and enhancer. The lacZ gene was used as a marker because its gene product, beta-galactosidase, is readily detected by X-gal histochemistry. Sixty neonatal (3 to 5 days old) and 45 adult (6 to 8 weeks old) C57BL/6 mice were investigated. Intestinal gene transfer was attempted with H5.010CMVlacZ by intraperitoneal (i.p.), intraluminal (IL), and intramural (i.m.) injection. Based on prior studies, the optimal dose of H5.010CMVlacZ was 1 x 10(8) plaque forming units (pfu/mL). Control animals received saline injections. Gene transfer on repeat administration of adenovirus has been shown to be prevented by neutralizing antibody. To determine if neonatal inoculation induced a humoral immune response, neonates (n = 5) that received i.p. injections were rechallenged with intravenous H5.010CMV alkphos, a similar adenoviral construct containing the alkaline phosphatase marker gene. Serum samples were analyzed by Western blot to detect the presence of adenoviral-specific antibody.
Gene transfer to neonatal small intestine was successful by IL gastric (n = 8/10), IL jejunal (n = 9/10) and i.p. (n = 10/10) routes 2 days after injection. Macroscopic staining was present in 90% of standardized 2-cm small bowel segments. Transgene expression was identified in intestinal smooth muscle, serosa, and epithelium. Gene transfer to the adult small intestine was successful by IL jejunal (n = 4/5), i.m. (n = 5/5), and i.p. (n = 1/5) injection of adenoviruslacZ with focal staining (< 5% of 2-cm segments) in epithelium including crypts, muscle, and serosa. Three weeks after i.p. H5.010CMVlacZ in neonates, intravenous injection with H5.010CMValkphos resulted in hepatic transgene expression (n = 4/5) that was indistinguishable from a primary intravenous inoculation; persistent, lacZ expression was not detectable in the liver or intestine (n = 0/5). Western blot analysis detected adenoviral-specific antibodies after adult IM but not after neonatal i.p. injection. Furthermore, 3 weeks after neonatal i.p. injection repeat administration by the i.m. route was successful (n = 4/ 4).
Gene transfer to neonatal and adult small intestine is feasible using recombinant adenovirus and is more efficient in neonates as indicated by increased surface area of marker gene expression, effectiveness of intraperitoneal delivery, and the ability to readminister recombinant adenovirus.
作者试图评估在新生和成年小鼠中使用重组腺病毒将基因体内转移至小肠的可行性。
H5.010CMVlacZ是一种复制缺陷型、E1基因缺失的人5型腺病毒,其在巨细胞病毒启动子和增强子的控制下含有lacZ基因。lacZ基因用作标记,因为其基因产物β-半乳糖苷酶可通过X-gal组织化学轻易检测到。研究了60只新生(3至5日龄)和45只成年(6至8周龄)C57BL/6小鼠。通过腹腔内(i.p.)、肠腔内(IL)和壁内(i.m.)注射H5.010CMVlacZ尝试进行肠道基因转移。基于先前的研究,H5.010CMVlacZ的最佳剂量为1×10⁸ 空斑形成单位(pfu/mL)。对照动物接受盐水注射。已证明重复给予腺病毒时,基因转移会被中和抗体阻止。为确定新生接种是否诱导体液免疫反应,对接受腹腔内注射的新生小鼠(n = 5)用静脉注射H5.010CMValkphos再次进行攻击,H5.010CMValkphos是一种类似的含有碱性磷酸酶标记基因的腺病毒构建体。通过蛋白质印迹法分析血清样本以检测腺病毒特异性抗体的存在。
注射后2天,通过肠腔胃内(n = 8/10)、肠腔空肠内(n = 9/10)和腹腔内(n = 10/10)途径成功将基因转移至新生小肠。在90%的标准化2厘米小肠段中存在宏观染色。在肠道平滑肌、浆膜和上皮中鉴定出转基因表达。通过肠腔空肠内(n = 4/5)、壁内(n = 5/5)和腹腔内(n = 1/5)注射腺病毒lacZ成功将基因转移至成年小肠,在上皮(包括隐窝、肌肉和浆膜)中有局灶性染色(<2厘米段的5%)。新生小鼠腹腔内注射H5.010CMVlacZ三周后,静脉注射H5.010CMValkphos导致肝脏转基因表达(n = 4/5),这与初次静脉接种无差异;在肝脏或肠道中未检测到持续的lacZ表达(n = 0/5)。蛋白质印迹分析在成年小鼠壁内注射后检测到腺病毒特异性抗体,但新生小鼠腹腔内注射后未检测到。此外,新生小鼠腹腔内注射三周后,通过壁内途径重复给药成功(n = 4/4)。
使用重组腺病毒将基因转移至新生和成年小肠是可行的,并且在新生小鼠中更有效,这表现为标记基因表达的表面积增加、腹腔内递送的有效性以及再次给予重组腺病毒的能力。